shouldiuse.io

VERDICT

Should I use Ambrosia Ventures?

Life sciences strategic advisory and M&A firm with a proprietary deal database of 2,500+ transactions. - ambrosiaventures.co

Depends. A reasonable fit for funded biotech, pharma, or device companies facing a first licensing or M&A decision who can absorb custom advisory fees. Early-stage startups without an asset to sell and teams wanting cheap self-serve deal data should not hire a boutique advisory.

Confidence

Medium. Based on 20+ public sources; all performance claims are self-reported and no independent client reviews were found.

Ratings

  • Value for moneyNo pricing or fees published anywhere
  • Ease of useService firm, not a tool
  • Feature depth
  • Support qualityNo client testimonials or reviews found
  • Security posture

Pricing

Not disclosed

ModelNot disclosed
Monthly feesNot disclosed
HardwareNot disclosed

Best for

  • Emerging biotechs exploring licensing or exit
  • Medical device companies seeking partnerships
  • BD teams wanting deal benchmarks with advisory support

Not for

  • Pre-seed startups with nothing to license or sell yet
  • Small teams wanting cheap self-serve deal data
  • Big pharma with established in-house BD and data subscriptions
  • Buyers expecting published rates or independent reviews

Gotchas - check before you buy

medium

No published rates — expect custom fees and per-engagement scoping with no benchmark to negotiate against

medium

Deal-count claims swing between 1,500+ and 2,500+ in their own content — verify data depth before paying

medium

Young firm: limited public evidence of closed transactions or named clients

low

Name collides with unrelated firms (Singapore VC, Indian LLP, defunct blood startup) — vet the entity

Pros and cons

Pros

  • Boutique advisory covering licensing, M&A execution, and partnerships
  • Claims proprietary database of 2,500+ verified deals in 12 therapeutic areas
  • Publishes free deal-valuation guides and benchmark calculators
  • Founder visibly active: speaking at BioTechX USA and investor events

Cons

  • No public pricing; engagements custom-negotiated with undisclosed fees
  • Founded 2023 — short track record for M&A execution claims
  • Own materials cite conflicting database sizes: 2,500+ vs 1,500+ deals
  • No independent client reviews; coverage is promotional profiles and directory listings

Sources & method

Analyzed 9/25/2026 - 9 sources - No known vulnerabilities found in the sources reviewed.

official x3review x2security x1news x3

Key stats

  • Feature depth: 3/5

    Rating

  • Not disclosed

    Starting price

  • 9

    Sources

  • Analyzed

  • Value for money. No pricing or fees published anywhere
  • Ease of use. Service firm, not a tool
  • Feature depth: 3/5. Claims 2,500+ deal database; unverified and self-contradicted
  • Support quality. No client testimonials or reviews found
  • Security posture: 2/5. No public security page found
  • 2023 Founded Michigan-based, per PitchBook
  • 2,500+ deals Claimed deal database Self-reported across 12 therapeutic areas
  • 2 Offices Detroit and New York
  • 0 Independent reviews None found in public sources

Pricing

Not disclosed

Security

No known vulnerabilities found in the sources reviewed.

What users say

No independent user reviews found; coverage consists of promotional listicles, directory profiles, and the founder's own posts.

Full analysis

Based on 20+ public sources; all performance claims are self-reported and no independent client reviews were found.

Boutique 2023 life-sciences M&A advisory; no public pricing or independent reviews. Fine for funded biotechs, skip if pre-deal.

Methodology

Based on 20+ public sources; all performance claims are self-reported and no independent client reviews were found.

Sources

  1. Ambrosia Ventures — Aboutambrosiaventures.co
    official
  2. Ambrosia Ventures — Homepageambrosiaventures.co
    official
  3. Ambrosia Ventures Company Profile — PitchBookpitchbook.com
    news
  4. 30 Innovative Companies to Watch in 2024 — Silicon Reviewthesiliconreview.com
    review
  5. Top Healthcare Marketing Consulting Companies — RevenueBaserevenuebase.ai
    review
  6. Ambrosia vs Evaluate Pharma — Deal Benchmarking Comparedcalculator.ambrosiaventures.co
    official
  7. BioTechX USA — Speaker listterrapinn.com
    news
  8. Ambrosia (young-blood startup) shuts down — Business Insiderbusinessinsider.com
    news
  9. Security pageambrosiaventures.co
    security

Rate this review

Anonymous. You can change your vote.

Loading votes…

Comments

One queue. No nested comments. Give a display name first. Limit: 200 words per comment and 7 comments per day. You can edit or delete yours.

Save a name to write a comment.

0 / 200 words

No comments yet.